New Study Links CGRP Migraine Injectables to 40% Higher Miscarriage Risk
A new observational study published in JAMA Neurology indicates that exposure to CGRP-targeted monoclonal antibodies, a class of injectable migraine preventatives approved in 2018, is associated with a 40% increased risk of spontaneous abortion in the first 20 weeks of pregnancy. The research, led by Anick Bérard, analyzed data from 7,579 pregnancies among commercially insured US women between 2018 and 2021. While the study found a significant association between these drugs and miscarriage, it did not establish causation, noting that severe migraine itself may contribute to the risk. In contrast, exposure to propranolol, another migraine preventive, showed no increased risk. Clinicians are urged to counsel patients of reproductive age on these potential risks while awaiting further safety data.
